---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060221"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:46:08.998835+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytomX Q3 revenue $26.4M, cash $194.1M; pipeline milestones on track

## Summary
- Revenue $26.4M vs $11.1M YoY; cash $194.1M (includes ~$30M from BVF financing, $16.8M Q3 burn).
- R&D expense $16.4M (-46% YoY); G&A $6.8M (-35% YoY); no net income or EPS disclosed.
- CX-904 Phase 1a dose escalation data expected H1 2024; backfilling cohorts initiated Q4 2023.
- CX-2051 IND filing by end of 2023; Phase 1 in solid tumors in 2024 with mCRC priority.
- BMS-986288 Phase 2 ongoing; proof-of-concept data in MSS CRC and NSCLC expected in 2024.

## SEC filing metadata
- accession: 0000950170-23-060221
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/0000950170-23-060221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/ctmx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060221
- JSON: https://secwatch.observer/filing/0000950170-23-060221.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060221.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: On November 7, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/0000950170-23-060221-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.